Cytokinetics announces Myqorzo prescribing information expanded with Phase 3 MAPLE-HCM data
CYTK•The FDA approved a supplemental new drug application updating the Myqorzo label with Phase 3 MAPLE-HCM data.
CYTK•The FDA approved a supplemental new drug application updating the Myqorzo label with Phase 3 MAPLE-HCM data.
Cytokinetics said the FDA approved an application updating Myqorzo prescribing information to include data from the Phase 3 MAPLE-HCM trial.